Bladder Cancer

Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.

The combination of durvalumab and chemotherapy improved outcomes compared with neoadjuvant chemotherapy alone for patients with muscle-invasive bladder cancer, according to the agent’s manufacturer.

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors.

Tumor mutational burden may help predict benefit of immune checkpoint inhibitor therapy for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

The FDA approved nogapendekin alfa inbakicept-pmln plus Bacillus Calmette-Guerin for the treatment of certain patients with bladder cancer, according to a press release from the manufacturer.

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

The combination of pembrolizumab plus enfortumab vedotin significantly extended OS and PFS as first-line treatment for adults with locally advanced or metastatic urothelial carcinoma, according to the manufacturers of both agents.

Patients with muscle-invasive bladder cancer receiving dose-dense methotrexate, vinblastine, doxorubicin and cisplatinhad improved OS at 5 years compared with gemcitabine and cisplatin, according to a presentation at ASCO Annual Meeting.